ACR staff can help members navigate questions on all areas of practice management.
Heading to D.C. for ACR Convergence 2024? Add Your Lawmakers to Your Itinerary
If you’re headed to Washington, D.C., this November for ACR Convergence 2024, plan now to schedule meetings with your members of Congress. Your voice as a constituent can help your lawmakers understand which policies are good for healthcare as they consider a critical end-of-year funding package.
Glucocorticoids Increase Infections, Mortality
Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.
Draft FDA Guidance No Longer Requires Biosimilar Switching Studies
The updated draft guidance, released in June, would accept an assessment of why data provided meet the switching standard to demonstrate interchangeability of biosimilars
Business of Rheumatology Manual: A Preview of What’s to Come
Revisions of the handbook to reflect an evolving healthcare landscape are underway, led by the Committee on Rheumatologic Care, Community Practice Council and Insurance Subcommittee. The first new chapters will be available in fall 2024.
Calling Young Rheumatologist Leaders
The ACR is seeking a representative to the Young Physician Section of the AMA House of Delegates who will join the ACR’s delegation at future HOD meetings and advance issues important to rheumatology.
FDA Approves 2 Upadacitinib Formulations for Children with pJIA & PsA
Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
3 AC&R Study Summaries: Lupus Fog, SSc Variance By Ethnicity & Tuberculosis Screening in New DMARD Users
Lupus Fog? By Laura C. Plantinga, PhD, Patricia P. Katz, PhD, S. Sam Lim, MD, MPH, C. Barrett Bowling, MD, MSPH, & Jinoos Yazdany, MD, MPH Why was this study done? Perceived cognitive impairment (i.e., lupus fog) is common in systemic lupus erythematosus (SLE). However, comprehensive, multidomain assessments of objective cognitive function are rarely performed….
What’s New in Large Vessel Vasculitis
The large vessel vasculitides were a major focus of the 21st International Vasculitis Workshop held in Barcelona in April. The biennial conference brings together specialists from multiple disciplines, including rheumatology, nephrology and immunology, to discuss cutting-edge vasculitis research. This article reviews important points regarding the pathogenesis, diagnosis and management of both giant cell arteritis and…
Summer 2024’s Awards, Appointments & Announcements in the World of Rheumatology
Dr. Megan Cooper Appointed Director of Pediatric Rheumatology & Immunology Division at WashU Megan A. Cooper, MD, PhD, a physician-scientist recognized internationally for her work in pediatric immunodeficiencies and immune dysregulation, took the reins of the Division of Pediatric Rheumatology and Immunology at Washington University School of Medicine, St. Louis, as director this past fall….
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 814
- Next Page »